Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?
Krystal Biotech (KRYS) reported strong Q2 2026 net income and earnings per share, primarily driven by its gene therapy, Vyjuvek. While these results highlight increased profitability, the article emphasizes that the core investment narrative still revolves around the successful global rollout of Vyjuvek and managing risks related to revenue volatility, margin pressure, and unpredictable treatment patterns. Investors are encouraged to consider these factors alongside the positive earnings.
State of Wyoming Buys New Stake in Krystal Biotech, Inc. $KRYS
The State of Wyoming recently acquired a new stake in Krystal Biotech, purchasing 4,767 shares valued at approximately $1.77 million during the second quarter. Krystal Biotech reported strong Q2 earnings, beating EPS estimates, and institutional investors now collectively own 86.29% of the company's stock. Analysts generally maintain a "Moderate Buy" rating for KRYS, with a consensus price target of $365.40, following several recent upgrades.
Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?
Krystal Biotech reported strong Q2 2026 net income and EPS, largely driven by its drug Vyjuvek. While these results bolster the company's investment narrative, the core risk remains the execution of Vyjuvek's global rollout and potential revenue volatility due to patient treatment patterns, pricing, or reimbursement. The recent UK marketing authorization for Vyjuvek underscores the importance of successful international expansion, alongside the less visible risk of unpredictable treatment pauses affecting return stability.
Krystal Biotech (NASDAQ:KRYS) Upgraded to "Moderate Buy" at Royal Bank Of Canada
Royal Bank of Canada upgraded Krystal Biotech (NASDAQ:KRYS) to a "moderate buy" rating, aligning with a generally bullish analyst consensus. The company, which has a market capitalization of $9.83 billion, recently reported quarterly earnings that beat expectations but revenue that slightly missed. Insider selling of shares has occurred, while institutional investors hold a significant portion of the stock.
Krystal Biotech (KRYS) Director Dino Rossi Sells 25,000 Shares
Krystal Biotech (KRYS) Director Dino Rossi sold 25,000 shares of the company on August 14, 2026, for approximately $8.23 million, reducing his direct ownership to 50,000 shares. This sale continues a trend of insider selling over the past year, with no insider buys reported, yet the stock is considered "Fairly Valued" by GuruFocus's proprietary model. Despite insider selling, institutional interest remains strong, with a majority of gurus increasing their positions, suggesting confidence in the company's long-term prospects.
Krystal Biotech(KRYS.US) Director Sells US$8.23 Million in Common Stock
Krystal Biotech (KRYS.US) Director, Daniel Meyer, sold 84,200 shares of common stock on August 13, 2026, for a total of $8.23 million. The shares were sold at an average price of $97.75. Following this transaction, Meyer directly owns 10,000 shares of the company.
Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock
Krystal Biotech Director Dino Rossi sold 25,000 shares of the company's stock on Friday, August 14th, at an average price of $329.12 per share, totaling $8.23 million. Following this transaction, Rossi's stake in the company decreased by 33.33% to 50,000 shares. Despite the insider selling, Krystal Biotech shares rose 1.2% on Friday, and analysts maintain a "Moderate Buy" rating with an average target price of $365.40.
Krystal Biotech, Inc. SEC Filing (Aug 14, 2026)
This article reports on a Form 144 SEC filing by Krystal Biotech, Inc. (KRYS) on August 14, 2026. The filing indicates a proposed sale of 25,000 shares of common stock with an aggregate market value of $8,306,750, acquired from the public market on September 22, 2017. The sentiment and impact of this filing are deemed neutral by StockTitan's AI analysis.
KRYSTAL BIOTECH, INC. : RBC INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $400
RBC Capital Markets has initiated coverage on Krystal Biotech, Inc. (KRYS.O) with an Outperform rating. The firm has set a target price of $400 for the biotechnology company. This announcement was made on August 14, 2026.
RBC Initiates Krystal Biotech at Outperform, With $400 Price Target
RBC Capital Markets has initiated coverage on Krystal Biotech with an Outperform rating and a $400 price target, citing strong positioning for future gains from its product VYJUVEK and a promising pipeline. The biotech company, which specializes in genetic medicines, recently reported Q2 2026 earnings with a net income and product revenue increase, despite missing FactSet's revenue estimates. Krystal Biotech is also developing several other product candidates for various diseases, including Cystic Fibrosis and solid tumors.
Krystal Biotech (KRYS) Earnings And Pipeline Progress Put Valuation Back In Focus
Krystal Biotech (KRYS) reported strong Q2 2026 earnings with net income of US$54.77 million and 24% net product revenue growth for VYJUVEK, leading to a significant year-to-date share price return. Despite a recent short-term decline, the company is trading below analyst price targets, and its expanding pipeline in various medical fields suggests potential for future revenue growth. The valuation debate centers on an estimated fair value of $361.67, driven by pipeline expansion and favorable healthcare dynamics for genetic therapies.
Krystal Biotech (KRYS) Earnings And Pipeline Progress Put Valuation Back In Focus
Krystal Biotech (KRYS) reported strong Q2 2026 results with net income of US$54.77 million and 24% net product revenue growth for VYJUVEK, contributing to significant year-to-date and 1-year share price returns. Despite a recent short-term dip, the company trades below analyst targets and intrinsic value estimates. Its pipeline expansion into lung disease, ophthalmology, oncology, and aesthetics, alongside favorable healthcare trends, positions it for future growth and diversified earnings.
Bank of America Corp DE Increases Stock Position in Krystal Biotech, Inc. $KRYS
Bank of America Corp DE significantly increased its stake in Krystal Biotech (NASDAQ:KRYS) by 36.6% in the first quarter, now owning 260,647 shares valued at $67.3 million. Other institutional investors also raised their positions, leading to institutional ownership of 86.29%. The company reported strong quarterly earnings of $1.79 per share, beating estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $361.56.
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript
Krystal Biotech (KRYS) reported strong Q2 2026 results, with net product revenue up 24% to $119.2 million, driven by VYJUVEK sales and expansion into community settings. The company achieved 730+ U.S. reimbursement approvals and is advancing a robust clinical pipeline, including registrational studies for ocular indications and oncology programs. Krystal Biotech is transitioning to a multi-product genetic medicines company, with several key data readouts and new registrational trial initiations expected in late 2026 and 2027.
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today
Krystal Biotech (NASDAQ: KRYS) has significantly outperformed the market over the last five years, with an average annual return of 42.63%. An initial investment of $1000 in KRYS five years ago would now be worth $5,893.89, demonstrating the power of compounded returns. The company currently holds a market capitalization of $9.69 billion.
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today
Krystal Biotech (NASDAQ: KRYS) has significantly outperformed the market over the last five years, with an average annual return of 42.63%. An investment of $1000 in KRYS stock five years ago would now be worth $5,893.89, demonstrating the power of compounded returns. The company currently has a market capitalization of $9.69 billion.
Renaissance Technologies LLC Has $2.48 Million Stock Position in Krystal Biotech, Inc. $KRYS
Renaissance Technologies LLC significantly increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 190.9% in the first quarter, now holding 9,600 shares valued at approximately $2.48 million. Other institutional investors have also adjusted their positions, with institutions collectively owning 86.29% of the stock. Analysts maintain a positive outlook with a "Moderate Buy" consensus rating and an average price target suggesting further upside from the current trading price.
California State Teachers Retirement System Has $6.76 Million Holdings in Krystal Biotech, Inc. $KRYS
The California State Teachers Retirement System increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 27.2% in the first quarter, now holding 26,186 shares valued at $6.76 million. Krystal Biotech reported strong Q1 earnings per share of $1.79, beating analyst estimates, although revenue slightly missed expectations. Analysts maintain a "Moderate Buy" rating with an average price target of $361.56 despite recent insider stock sales.
Krystal Biotech (KRYS) After Its Q2 Beat Is The Valuation Case Still Intact
Krystal Biotech (KRYS) reported strong Q2 2026 results, exceeding analyst expectations with robust Vyjuvek sales and expanding market reach. Despite a recent short-term share price dip, longer-term performance remains strong. The article discusses two valuation perspectives: one suggesting the stock is 10.2% undervalued based on a narrative of pipeline expansion and favorable healthcare dynamics, and another from a DCF model indicating it is significantly undervalued at $1,054.32 compared to its current price of $324.77.
The Manufacturers Life Insurance Company Cuts Stake in Krystal Biotech, Inc. $KRYS
The Manufacturers Life Insurance Company reduced its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.2% in the first quarter, selling 4,560 shares and retaining 36,069 shares valued at approximately $9.3 million. Despite beating EPS estimates, Krystal Biotech's revenue fell short of analyst forecasts, though demand for VYJUVEK remains strong. Analysts maintain a "Moderate Buy" rating with an average price target of $360.67, recognizing risks like higher expenses and international reimbursement negotiations.
KRYSTAL BIOTECH INC : BOFA GLOBAL RESEARCH CUTS PRICE OBJECTIVE TO $392 FROM $396
BofA Global Research has lowered its price objective for Krystal Biotech Inc. (KRYS.O) from $396 to $392. This adjustment reflects a revised outlook from the research firm regarding the biotechnology company. The article provides this key financial update from Reuters.
Krystal Biotech Inc Unsponsored BDR Revenue Breakdown – BMFBOVESPA:K1YS34
This article provides a revenue breakdown for Krystal Biotech Inc Unsponsored BDR (K1YS34). It highlights that the company generated 2.14 billion BRL last year, primarily from its Genetic Medicines segment and the United States market. The information is presented within the context of TradingView's financial data offerings.
Krystal Biotech (KRYS) Stock Price Drops As Premium Expectations Reset
Krystal Biotech's stock price dropped 8% after its Q1 2026 earnings report, despite solid revenue and profit growth. This decline is attributed to a reset in investor expectations rather than poor financial performance. While the company's gene therapy, VYJUVEK, shows strong gross margins and continued demand, concerns about international reimbursement friction and increased general & administrative costs contributed to the market's reaction.
Krystal Biotech Shares Fall After Q2 Product Revenue Miss
Krystal Biotech (KRYS) shares declined after the company reported second-quarter product revenue of $119.2 million, which missed FactSet estimates of $120.9 million. Despite the revenue miss, the company's Q2 EPS of $1.79 exceeded the FactSet estimate of $1.62. The biotechnology company focuses on genetic medicines and recently had its commercial product, VYJUVEK, approved in the United States and Europe for treating dystrophic epidermolysis bullosa.
Krystal Biotech Releases Q2 2026 Financial Results
Krystal Biotech (KRYS) announced strong Q2 2026 financial results, with diluted earnings per share of $1.79, beating the consensus estimate of $1.69. The company reported net income of $54.8 million and generated $119.2 million in revenue, a 24.0% increase year-over-year. This performance reflects increasing adoption of its genetic medicine platform and has led to an optimistic outlook from Wall Street analysts.
Krystal Biotech (KRYS) Q2 2026 Earnings
Krystal Biotech (KRYS) reported its Q2 2026 earnings, missing both EPS and revenue estimates. Despite the miss, the company highlighted 24% revenue growth for its product VYJUVEK and anticipates several pipeline readouts over the next 12 to 18 months, signaling a potential shift towards becoming a multi-product company.
Krystal Biotech Q2 Earnings Beat Expectations
Krystal Biotech reported Q2 GAAP EPS of $1.79, exceeding expectations by $0.16, and achieved $119.22 million in revenue, a 24.1% year-over-year increase, despite a slight miss on revenue estimates. The company's product VYJUVEK has generated $965.9 million in global revenue since launch, demonstrating strong market acceptance. Krystal Biotech provided FY 2026 guidance for non-GAAP R&D and SG&A expenses between $175 million and $195 million, reflecting confidence in future investments.
Krystal Biotech stock falls 7% on revenue miss despite earnings beat
Krystal Biotech (NASDAQ:KRYS) reported Q2 results with adjusted EPS of $1.79, beating analyst estimates, but product revenue of $119.2 million missed the forecast of $122.3 million, causing its stock to fall 7.65% in pre-market trading. Despite the revenue miss, the company's VYJUVEK product showed strong performance with a 95% gross margin, and the company maintains a strong balance sheet with $1.1 billion in cash and investments, while also providing full-year 2026 guidance for adjusted expenses.
Krystal Biotech 2Q 2026: Revenue $119.22M, EPS $1.79— 10-Q Summary
Krystal Biotech reported strong second-quarter 2026 results, with revenue reaching $119.22 million and diluted EPS at $1.79, largely driven by increased VYJUVEK sales and successful market expansions. The company achieved significant year-over-year growth in revenue, net income, and EPS, supported by high gross margins and advancing R&D pipeline. VYJUVEK's expansion into new markets like the EU and Japan, along with new approvals, continues to fuel its performance.
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates
Krystal Biotech (KRYS) reported strong Q2 2026 earnings, beating the Zacks Consensus Estimate with $1.79 per share and exceeding revenue expectations with $119.22 million. Despite this positive performance and a significant year-to-date stock increase of 38.4%, the company currently holds a Zacks Rank #4 (Sell) due to unfavorable estimate revisions prior to the earnings release. Investors are advised to consider management's commentary and industry outlook for future stock movements.
Earnings Flash (KRYS) Krystal Biotech, Inc. Reports Q2 Revenue $119.2M, vs. FactSet Est of $120.9M
Krystal Biotech, Inc. (KRYS) reported Q2 revenue of $119.2 million, falling short of FactSet's estimate of $120.9 million. The company is an integrated, commercial-stage biotechnology firm focused on genetic medicines, with its commercial product VYJUVEK approved for dystrophic epidermolysis bullosa. Analysts currently have a "BUY" consensus for KRYS with an average target price of $382.86.
Krystal Biotech Inc (KRYS) Valuation: PE, PB & Fair Value Analysis
Krystal Biotech Inc (KRYS) currently has a valuation score of 7.39, placing it 177th out of 385 in the Biotechnology & Medical Research industry. Its P/E ratio stands at 44.04, significantly differing from its recent high and low. Data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Krystal Biotech slides as investors appear to reset ahead of earnings
Krystal Biotech (KRYS) saw an 8.7% decline in its stock price, potentially due to traders taking profits and reducing risk ahead of its Q2 2026 earnings report on August 3. The company previously reported strong Q1 2026 results with $116.4 million in revenue and $55.9 million in net income, and is set to join the S&P MidCap 400. Insider trading activity shows numerous sales, and analysts have set a median price target of $344.0.
Krystal Biotech earnings in focus as Vyjuvek expansion accelerates By Investing.com
Krystal Biotech Inc. is set to announce its second-quarter results, with analysts anticipating EPS of $1.75 on revenue of $122.61 million, indicating strong year-over-year growth for its flagship product Vyjuvek. Investors will closely monitor the company's ability to sustain U.S. growth and accelerate international expansion, particularly in key European and Asian markets. The focus will also be on management's reiteration of operating expense guidance and the stability of gross margins as Krystal scales globally.
Krystal Biotech Drops 5.9% Amid Sector-Wide Selling
Krystal Biotech (KRYS) shares fell 5.9% to $345.35 on Friday, July 31, 2026, as part of a broader sector-wide selloff impacting biotechnology stocks. This decline, mirroring losses in other biotech firms like Madrigal Pharmaceuticals and Cytokinetics, suggests broad-based selling pressure rather than company-specific concerns. Investors are advised to monitor the biotech sector's stability and any potential company-specific catalysts for Krystal Biotech.
How Krystal Biotech Inc. (KRYS) Affects Rotational Strategy Timing
This article analyzes Krystal Biotech Inc. (KRYS) and its impact on rotational strategy timing, identifying a mid-channel oscillation pattern. It highlights strong near-term sentiment while suggesting neutrality mid-term and a positive long-term bias. The analysis provides specific institutional trading strategies for long, breakout, and short positions, along with multi-timeframe signal analysis indicating support and resistance levels.
US High Growth Tech Stocks To Watch In July 2026
Despite a recent market drop, the US market is up 14% over the past year with projected annual earnings growth of 17%, indicating a dynamic environment for high-growth tech stocks. This article highlights three promising tech companies: Krystal Biotech (KRYS), Palantir Technologies (PLTR), and Western Digital (WDC), detailing their operations and significant growth potential driven by innovation and strategic market positioning. These companies are among the top 10 high-growth tech firms identified in the US.
US High Growth Tech Stocks To Watch In July 2026
This article identifies top high-growth tech stocks in the US for July 2026, despite a recent market drop. It highlights ten companies with strong revenue and earnings growth projections, including detailed analyses of Krystal Biotech, Palantir Technologies, and Western Digital, based on their innovative strategies and financial performance. The report emphasizes the importance of evaluating companies with strong innovation and adaptability in the current dynamic market.
Krystal Biotech (KRYS) Is Up 7.9% After S&P 400 Move And New KB801 Patent Filing Update
Krystal Biotech (KRYS) stock rose 7.9% following its inclusion in the S&P 400 index and an update on its KB801 gene therapy patent filing. The patent filing included single-patient data from a discontinued study for neurotrophic keratitis, with the company emphasizing the data's early nature and relevance to patent protection, not efficacy conclusions. This S&P 400 move increases potential exposure to mid-cap index funds, affecting trading dynamics, while the core investment narrative still relies on VYJUVEK's success and pipeline development.
Krystal Biotech (KRYS) After The KB801 Update And Why Valuation Still Splits Opinion
Krystal Biotech (KRYS) recently shared new single-patient data regarding its KB801 gene therapy for neurotrophic keratitis, despite the study being discontinued. The company's stock has shown strong momentum, but valuation opinions are split, with some analysts considering it slightly overvalued at $361.67, while a discounted cash flow model suggests it is significantly undervalued. The article highlights both the optimistic outlook based on pipeline developments and concerns regarding concentration risks.
Krystal Biotech Inc (KRYS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Krystal Biotech Inc (KRYS), detailing its current price momentum, support and resistance levels, and various technical indicator signals. The stock's price momentum score is 3.84, with trading between 331.98 support and 389.51 resistance. Moving averages overwhelmingly show buy signals, while other indicators present a mixed view, with an overall neutral signal based on today's analysis.
Krystal Biotech, Inc. (KRYS) Stock Analysis: Biotechnology Pioneer with 12.40% Potential Upside
Krystal Biotech, Inc. (KRYS) is a commercial-stage biotechnology company with a market capitalization of $9.88 billion, known for its genetic medicines like VYJUVEK for dystrophic epidermolysis bullosa. The company shows strong financial performance with a 31.90% revenue growth rate, 19.90% ROE, and a positive EPS of 7.48. Analysts have a favorable outlook with a 12.40% potential upside, and its diverse pipeline, including KB803 and KB407, positions it for continued future growth.
Krystal Biotech, Inc. Revenue Breakdown – NASDAQ:KRYS
Krystal Biotech, Inc. (NASDAQ: KRYS) generated $389.13 million USD in revenue last year, primarily from its Genetic Medicines segment. The company's revenue increased from $290.51 million USD in the previous year, with the United States being the greatest contributor to its sales.
KRYS|Krystal Biotech Inc|Price:335.190|Chg%:+7.690
Krystal Biotech Inc. (KRYS) shows strong fundamentals, high growth potential, and is considered fairly valued in the Biotechnology & Medical Research industry, ranking 7 out of 386. The company's revenue has grown consistently, and its latest net income leads the industry. Analysts currently rate the stock as "Buy" with a price target indicating an upside.
KRYS|Krystal Biotech Inc|Price:335.190|Chg%:+7.690
Krystal Biotech Inc (KRYS) has received a "Buy" rating from multiple analysts, with a highest price target of $353.21, indicating an expected upward trend in its stock price. The company exhibits strong fundamentals, including high revenue and profit growth, and its stock is considered fairly valued within the Biotechnology & Medical Research industry. Despite recent weak market performance, institutional ownership is very high, suggesting strong confidence from professional investors.
Krystal Biotech, Inc. (KRYS) stock price, news, quote and history
This article provides a comprehensive overview of Krystal Biotech, Inc. (KRYS), including its current stock price, financial statistics, and company profile. It details the company's focus on genetic medicines, its commercialized product VYJUVEK, and its pipeline of drug candidates for various conditions. The report also includes performance metrics, earnings trends, analyst insights, and comparisons with similar biotechnology companies.
Krystal Biotech, Inc.(NasdaqGS:KRYS) added to S&P 400 - Biotechnology
Krystal Biotech, Inc. (NasdaqGS:KRYS) has been added to the S&P 400 index, specifically within the Biotechnology sector. This move comes as part of broader index changes, with Krystal Biotech replacing Taylor Morrison Home in the S&P MidCap 400. The company, which is a commercial-stage biotechnology firm, also recently received UK MHRA approval for its gene therapy, VYJUVEK, for treating dystrophic epidermolysis bullosa.
Krystal Biotech, Inc. (KRYS) stock price, news, quote and history
This article provides a comprehensive overview of Krystal Biotech, Inc. (KRYS), a commercial-stage biotechnology company. It details the company's current stock performance, key financial metrics, product pipeline focusing on genetic medicines, and analyst insights. The information covers historical data, recent news, and comparisons with similar companies in the biotechnology sector.
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) announced it will report its second quarter 2026 financial results on Monday, August 3, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update. A replay of the webcast will be available for at least 30 days on the company's website.
Krystal Biotech sets Aug. 3 webcast before U.S. markets open
Krystal Biotech (NASDAQ: KRYS) announced it will report its second-quarter 2026 financial results on Monday, August 3, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:30 a.m. ET on the same day for investors and the public. A replay of the webcast will be available for at least 30 days on the Investors section of the company's website.
